Eosinophilic Esophagitis Market By Treatment Type (Corticosteroids, Proton Pump Inhibitors (PPI), Biologics, Elimination Diets), By Route of Administration (Oral, Intravenous, Topical), By End-User (Hospitals, Clinics, Home Care Settings), By Age Group (Pediatric, Adult, Geriatric), By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Eosinophilic Esophagitis Market was valued at USD 0.8 billion in 2023 and will surpass USD 1.9 billion by 2030; growing at a CAGR of 12.4% during 2024 - 2030.

Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, often triggered by food allergens and environmental factors. It results in esophageal dysfunction, causing difficulty swallowing, food impaction, and esophageal narrowing. With increasing diagnosis rates and a growing understanding of the condition, the EoE market is expanding rapidly. This market is driven by various factors including the rise in food allergies, better diagnostic techniques, and the development of novel therapies, making it a significant area of focus for pharmaceutical companies, healthcare professionals, and researchers alike.

Corticosteroids Segment Is Largest Owing to Established Efficacy

Among the various treatment options for EoE, corticosteroids remain the largest segment due to their proven effectiveness in reducing inflammation in the esophagus. These anti-inflammatory drugs help manage the condition by decreasing eosinophil activity and suppressing the immune response. Corticosteroids are widely prescribed due to their relatively lower cost and availability in various forms, including oral and topical treatments. Despite the development of new therapies, corticosteroids continue to be a first-line treatment for most EoE patients.

Corticosteroids offer immediate relief from the symptoms of EoE, and are often used in conjunction with other treatments. While long-term use is generally avoided due to potential side effects, corticosteroids remain essential in the management of acute flare-ups. Their widespread use and high efficacy make them the dominant treatment for many EoE patients, particularly in the pediatric and adult demographics, where they provide significant symptomatic relief.

Oral Route of Administration Is Fastest Growing Due to Patient Convenience

The oral route of administration is the fastest growing segment in the EoE treatment market. Oral therapies, including corticosteroids and proton pump inhibitors (PPIs), offer significant advantages in terms of patient compliance and ease of use. Oral medications are more convenient compared to intravenous and topical treatments, making them the preferred choice for many patients, especially in outpatient and home care settings. As patients are increasingly seeking therapies that can be self-administered at home, the demand for oral formulations continues to rise.

The ease of administration and the non-invasive nature of oral treatments contribute significantly to their growing popularity. With the expanding market for oral biologics and oral corticosteroids, the segment is projected to maintain its rapid growth trajectory. As new oral therapies enter the market, this segment will likely see continued innovation, driving both market growth and patient satisfaction.

Hospitals Segment Is Largest Owing to High Treatment Demand

Hospitals remain the largest end-user segment for EoE treatments. The complex nature of the disease and the need for specialized care, such as endoscopy, biopsy, and intravenous treatments, make hospitals the primary setting for diagnosis and initial management. Hospitals are equipped with the necessary infrastructure and medical staff to provide comprehensive care, including the administration of biologics and intravenous therapies, which are often needed in severe cases of EoE. Moreover, hospitals are the preferred location for monitoring patients undergoing advanced treatments and for managing complications that may arise from chronic conditions like EoE.

Hospitals offer the advantage of access to a wide range of medical resources, including multidisciplinary teams, diagnostic tools, and support for intensive treatments. As a result, this segment continues to dominate, with hospitals driving the largest share of the EoE treatment market, especially in developed regions where healthcare infrastructure supports high patient volumes.

Pediatric Age Group Is Fastest Growing Due to Increasing Diagnosis Rates

The pediatric age group is the fastest growing segment in the EoE market, driven by an increase in the diagnosis of EoE in children. Early identification of EoE has become more common as healthcare professionals gain a better understanding of the condition and as pediatricians become more aware of the symptoms, such as feeding difficulties and failure to thrive. As the number of children diagnosed with EoE increases, the demand for age-appropriate treatments, such as oral corticosteroids and biologic therapies, continues to rise.

The rise in pediatric EoE cases is also linked to the growing prevalence of food allergies among children. The need for pediatric-specific interventions, including tailored treatment protocols and specialized care, is pushing the demand for treatments specifically designed for this age group. As a result, the pediatric segment is expected to see rapid growth in the coming years.

North America Is Largest Region Due to Advanced Healthcare Infrastructure

North America remains the largest region in the EoE market due to the presence of advanced healthcare infrastructure, high healthcare expenditure, and the availability of cutting-edge diagnostic and therapeutic options. The United States, in particular, has a high diagnosis rate of EoE, driven by increasing awareness among healthcare providers and the population. The growing availability of biologics and novel therapies is also contributing to the rapid market growth in this region.

The high prevalence of food allergies and gastrointestinal conditions in North America further propels the demand for EoE treatments. Additionally, the regulatory environment in the U.S. supports innovation in the treatment of chronic diseases, further accelerating market growth. North America will continue to dominate the market as new treatments for EoE are introduced and the awareness of the disease increases across the region.

Competitive Landscape and Leading Companies

The EoE treatment market is highly competitive, with several key pharmaceutical companies dominating the landscape. Leading players in the market include AstraZeneca, Sanofi, Pfizer, and Takeda, which have made significant advancements in the development of biologics and novel corticosteroids. These companies are driving innovation, focusing on both the improvement of existing therapies and the introduction of new treatment options that cater to the specific needs of EoE patients.

The competitive landscape is characterized by strategic partnerships, mergers and acquisitions, and a strong pipeline of therapies in clinical trials. With a growing emphasis on biologic therapies and personalized treatment approaches, these companies are well-positioned to capitalize on the expanding EoE market. Furthermore, the emergence of new biologic drugs and advancements in diagnostic technologies are expected to intensify competition, driving further growth in the market. As the market continues to evolve, companies that can offer effective, convenient, and patient-friendly solutions will have a significant advantage.

Recent Developments:

• In 2023, AstraZeneca and Sanofi announced new data supporting the use of Dupixent (dupilumab) as a treatment for Eosinophilic Esophagitis, reinforcing its role as a leader in biologic therapy
• In 2023, Takeda Pharmaceuticals acquired Nimbus Therapeutics, aiming to enhance its pipeline in immunology and gastrointestinal diseases, including Eosinophilic Esophagitis.
• GSK is advancing the development of an oral biologic drug for EoE, with phase III trials expected to conclude by late 2024. This drug aims to address gaps in current biologic therapies for chronic inflammation.
• Regeneron Pharmaceuticals and Amgen have entered into a partnership to co-develop Eosinophilic Esophagitis therapies, focusing on novel monoclonal antibodies that target eosinophil activity in the esophagus.
• In 2024, the U.S. FDA approved a new proton pump inhibitor (PPI) for use in Eosinophilic Esophagitis, which promises to offer a more targeted and effective treatment for managing symptoms and preventing flare-ups.

List of Leading Companies:

• AstraZeneca
• Sanofi
• Pfizer
• Takeda Pharmaceuticals
• GlaxoSmithKline (GSK)
• Allergan
• AbbVie
• Regeneron Pharmaceuticals
• Bayer AG
• Novartis
• Eli Lilly and Co.
• Amgen
• Biogen Inc.
• Teva Pharmaceutical Industries

Report Scope: